The Effect of Atorvastatin on the Human Lens After 52 Weeks of Treatment
Authors:
- 1 March 1998
- journal article
- other
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 3 (1) , 71-76
Abstract
Background: The effect of atorvastatin calcium (Lipitor, Parke-Davis, Morris Plains, NJ) on the crystalline lenses of hypercholesterolemic patients was evaluated and compared with that of lovastatin after 52 weeks of treatment to reduce cholesterol levels. Methods and Results: Six hundred ninety-six atorvastatin-treated and 235 lovastatin- treated patients completed a large safety study that included an ophthalmologic examina tion. Efficacy was evaluated as mean percent change from baseline in low-density lipopro tein (LDL) cholesterol. Patients received atorvastatin, 10 or 20 mg, or lovastatin, 20 or 40 mg, once daily for either 36 or 52 weeks. Patients were evaluated by slit-lamp examination, and a standardized format was used to describe the findings. Best corrected visual acuity was measured using the Snellen chart. Patients treated with atorvastatin had significantly ( P ≤ .05) greater decreases in LDL cholesterol than those treated with lovastatin (37% vs 29%). Although some patients in both groups experienced various lenticular opacities, none were considered unexpected. In addition, there were no significant (P ≤ .05) differences in the distribution of cortical opacities and spokes right eye (OD) and left eye (OS) and posterior subcapsular opacity (OS) between the atorvastatin and lovastatin groups. In general, the percent deterioration in best corrected visual acuity was similar in both groups. Overall, there were no clinically significant differences in the development of lenticular opacity between patients treated with atorvastatin and those treated with lovastatin. Conclusions: Treatment with atorvastatin, 10 or 20 mg, significantly reduced LDL-cholesterol ( P < .05) and was not associated with an increased risk of lenticular opacity development compared with lovastatin, a widely prescribed compound in the same class of drugs.Keywords
This publication has 15 references indexed in Scilit:
- Comparison of One-Year Efficacy and Safety of Atorvastatin Versus Lovastatin in Primary HypercholesterolemiaThe American Journal of Cardiology, 1997
- Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)JAMA, 1993
- The Human Lens after 48 Weeks of Treatment with LovastatinNew England Journal of Medicine, 1990
- Preclinical evaluation of lovastatinThe American Journal of Cardiology, 1988
- The clinical efficacy and safety of lovastatin and MK-733--an overviewEuropean Heart Journal, 1987
- The influence of mevinolin on the adrenal cortical response to corticotropin in heterozygous familial hypercholesterolemia.Proceedings of the National Academy of Sciences, 1985
- Source of cholesterol for the ocular lens, studied with U18666A: A cataract-producing inhibitor of lipid metabolismExperimental Eye Research, 1983
- Changes in lipid distribution in the human lens with the development of cataractExperimental Eye Research, 1981
- III. CataractSurvey of Ophthalmology, 1980